Mylan just asked a court to clear the way for a Wegovy generic. Hold the applause until we count what's still standing in the way. You're on GLP-1 Daily. Today we've got a patent fight, state AGs eyeing Chinese suppliers, an 'eye stroke' warning, and the question of whose clock any of it actually runs on. Mylan first. Let's see how short that road really is. Blake Brittain, over at Reuters, has the details. Mylan went to federal court Friday asking a judge to declare that its generic Wegovy doesn't infringe Novo's patent claims. And somewhere, a patient just googled 'generic Wegovy price.' Put the phone down. This is one declaratory-judgment action aimed at one slice of a patent thicket. What I want to know is how many Novo patents are still standing between this filing and a pen on a pharmacy shelf. That number should be in the headline. Yeah, and that gap lands hardest on the seniors in Medicare's so-called temporary access pathway. If a generic's years out no matter how this suit goes, 'temporary' is the only affordability lever they've got, and it has an expiration date. I'll give the filing a little more credit than that, though. As Reuters lays out, generic makers have to take on the brand's patents in court before they can legally sell a cheaper copy. If Mylan's paying lawyers now, they see a real market and a real opening. A real market for Mylan. What a win would actually buy the patient, we'll get to in the Step Back. So Mylan's asking a court to say its proposed generic Wegovy doesn't infringe a Novo Nordisk patent. If Mylan wins, does that finally mean a lower-cost version is headed to pharmacies? Not necessarily. Reuters reports Mylan is seeking a declaratory judgment in Delaware over a newly issued Novo Nordisk patent. Basically, Mylan wants a judge to clear its proposed generic from that specific patent claim before Novo can use it to block the product. But this sits inside a much bigger patent fight. IP Fray reports Novo sued Mylan back in January 2023, after Mylan filed an abbreviated new drug application for a generic Wegovy, and that case initially involved five patents. In a 2025 ruling, the Delaware court found Mylan’s proposed label didn't induce infringement of one Novo patent, according to the court decision. Still, Bloomberg Law reported earlier this year that Novo and Mylan were fighting over trial timing for so-called second-generation Wegovy patents, with Novo pushing for a trial no earlier than 2027. So a win on this newer patent could knock out one obstacle and cut some uncertainty for Mylan, but on its own it wouldn't settle every remaining patent issue around a generic. For patients, it could matter a lot for competition down the road, but it doesn't change what a pharmacy can dispense today. If you're on Wegovy or thinking about it, ask your prescriber which options are actually available to you right now. So the key distinction is clearing one patent versus clearing the whole path to launch? Exactly. Watch whether the court decides this new patent dispute in Mylan’s favor, and watch the older, wider case over the other Wegovy patents. Bloomberg Law said the window for finishing appeals could matter ahead of a cited 2031 patent expiration, which is one reason a court win can still be just one step in a longer process. Tennessee Star, with Tom Pappert:
Tennessee Attorney General Jonathan Skrmetti announced this week that his office joined 19 other state attorneys general in a letter expressing concern over potential national security risks posed by Chinese suppliers of glucagon-like peptide-1 (GLP-1) weight loss drugs, warning of reported ties to fentanyl precursor manufacturers, as well as injections being imported to the United States under false labels.
Twenty attorneys general, one letter to Marco Rubio. And what stopped me is where they trace the problem: the FDA's own Green List from September 2025, which let certain Chinese suppliers ship GLP-1 ingredients in without advance scrutiny. So the fast lane was federal. And the FDA has already warned one Green List company, Harbin Jixianglong Biotech. So this one isn't theoretical. But keep the categories separate. You've got licensed compounders with state inspectors. You've got organized-crime contraband. And now there are API suppliers with reported fentanyl-precursor ties, shipping under false labels. Those are different problems. Lump them all together as knock-offs and you erase the patients who were buying legally from that first group. And nobody orders semaglutide out of a mislabeled box for the thrill of it. With that Mylan generic still years from a shelf, the gray market is where the price is. "Reported" ties, though. I want to know who did the reporting before this hardens into a talking point. Fair. And a letter to the National Security Adviser might tighten a border. It won't take a dollar off anyone's copay. From Cheyenne R. Ubiera at Daily Express US:
Dozens of Americans have filed personal injury lawsuits against the makers of GLP-1s such as Ozempic, Wegovy, and Mounjaro, claiming they weren't properly warned of the risk of a rare kind of sudden vision loss known as nonarteritic anterior ischemic optic neuropathy, or NAION. Researchers have been studying the link between GLP-1s and NAION in recent years, following a safety signal reported by a Boston health center in 2024.
Sunday's Daily Express piece calls it an 'eye stroke.' The clinical name is NAION, and it means sudden vision loss. There are now dozens of personal-injury suits against Novo and Lilly. And the signal itself? A Boston health center, back in 2024. Which is the sequencing the headline skips. The signal's two years old. What's new is the litigation around it, and no study has shown these drugs actually cause it. Sure, but 'no study has proven' is cold comfort in an exam room. Novo says it'll act 'should emerging safety data warrant' it. Until then, who's holding the uncertainty? The patient signing the consent form, and none of it's on the label. Speaking as someone on one of these drugs, I want my doctor to bring it up. I don't want a lawsuit wave deciding how scared I should be. And watch the payers. Litigation risk is exactly the kind of excuse that keeps a prior-auth form frozen another year. Regulators, courts, plans, Mylan's patent fight. Everybody's running on their own clock. The patient's the only one on real time. Got feedback, a story idea, or a correction for GLP-1 Daily? Email us at g-l-p-one-daily at lantern podcasts dot com. We’d love to hear from you.
Links to every story are in the show notes, so check out the ones that caught your attention. That’s GLP-1 Daily for today. We’ll be back tomorrow. This is a Lantern Podcast.